This trial is testing a new drug to treat people who have developed a complication of cirrhosis called acute kidney injury. The drug will be given through an IV, and the goal is to see if it is safe and effective.
2 Primary · 18 Secondary · Reporting Duration: From Day 1 infusion start to Last Day of infusion end
100 Total Participants · 5 Treatment Groups
Primary Treatment: OCE-205 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Toronto General Hospital||100.0%|
|Did not meet criteria||100.0%|